Cargando…
New Approaches to Tay-Sachs Disease Therapy
Tay-Sachs disease belongs to the group of autosomal-recessive lysosomal storage metabolic disorders. This disease is caused by β-hexosaminidase A (HexA) enzyme deficiency due to various mutations in α-subunit gene of this enzyme, resulting in GM2 ganglioside accumulation predominantly in lysosomes o...
Autores principales: | Solovyeva, Valeriya V., Shaimardanova, Alisa A., Chulpanova, Daria S., Kitaeva, Kristina V., Chakrabarti, Lisa, Rizvanov, Albert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256099/ https://www.ncbi.nlm.nih.gov/pubmed/30524313 http://dx.doi.org/10.3389/fphys.2018.01663 |
Ejemplares similares
-
Extracellular vesicles in the diagnosis and treatment of central nervous system diseases
por: Shaimardanova, Alisa A., et al.
Publicado: (2019) -
Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches
por: Shaimardanova, Alisa A., et al.
Publicado: (2020) -
Serum Cytokine Profile, Beta-Hexosaminidase A Enzymatic Activity and GM(2) Ganglioside Levels in the Plasma of a Tay-Sachs Disease Patient after Cord Blood Cell Transplantation and Curcumin Administration: A Case Report
por: Shaimardanova, Alisa A., et al.
Publicado: (2021) -
Production and Application of Multicistronic Constructs for Various Human Disease Therapies
por: Shaimardanova, Alisa A., et al.
Publicado: (2019) -
Functionality of a bicistronic construction containing HEXA and HEXB genes encoding β-hexosaminidase A for cell-mediated therapy of GM2 gangliosidoses
por: Shaimardanova, Alisa A., et al.
Publicado: (2021)